Cooper Co stock kpis
Want to see COO full AI Analyst Report?
Revenue by Segment
Cooper Co reported revenue by segment of $1.07B in Q3 FY2026, down 1.4% from Q2 FY2026 and up 0.6% year over year. The highest value was $1.08B in Q2 FY2026.
Shows how different parts of the business contribute to overall sales, highlighting strengths and potential areas for growth within the company's diverse operations.
CooperVision is the steady-growth engine—consistent organic lens demand and new product momentum (MiSight, daily silicone hydrogel) underpin resilience even as Asia softness and near-term margin pressure from FX, tariffs and inventory optimization bite. CooperSurgical is the faster-growth lever—fertility, genomics and capital equipment have materially lifted contribution since 2022, and management’s strategic review (broad external interest) could unlock value or introduce execution risk. Monitor how litigation payouts and any transaction proceeds affect buybacks, FCF allocation and near-term margin recovery.
COO Revenue by Segment
| Period | CooperVision | CooperSurgical | Total |
|---|---|---|---|
| Q3 FY2026Jul 31, 2026 | $717.00M | $349.20M | $1.07B |
| Q2 FY2026Apr 30, 2026 | $723.50M | $358.00M | $1.08B |
| Q1 FY2026Jan 31, 2026 | $695.10M | $329.00M | $1.02B |
| Q4 FY2025Oct 31, 2025 | $709.60M | $355.60M | $1.07B |
| Q3 FY2025Jul 31, 2025 | $718.40M | $341.90M | $1.06B |
| Q2 FY2025Apr 30, 2025 | $669.60M | $332.70M | $1.00B |
| Q1 FY2025Jan 31, 2025 | $646.10M | $318.60M | $964.70M |
| Q4 FY2024Oct 31, 2024 | $676.40M | $342.00M | $1.02B |
| Q3 FY2024Jul 31, 2024 | $675.60M | $327.20M | $1.00B |
| Q2 FY2024Apr 30, 2024 | $635.90M | $306.70M | $942.60M |
| Q1 FY2024Jan 31, 2024 | $621.50M | $310.10M | $931.60M |
| Q4 FY2023Oct 31, 2023 | $622.90M | $304.20M | $927.10M |
| Q3 FY2023Jul 31, 2023 | $630.20M | $300.00M | $930.20M |
| Q2 FY2023Apr 30, 2023 | $589.30M | $288.10M | $877.40M |
| Q1 FY2023Jan 31, 2023 | $581.30M | $277.20M | $858.50M |
| Q4 FY2022Oct 31, 2022 | $561.70M | $286.30M | $848.00M |
| Q3 FY2022Jul 31, 2022 | $566.30M | $277.10M | $843.40M |
| Q2 FY2022Apr 30, 2022 | $553.80M | $276.00M | $829.80M |
| Q1 FY2022Jan 31, 2022 | $561.50M | $225.70M | $787.20M |
| Q4 FY2021Oct 31, 2021 | $564.90M | $194.20M | $759.10M |
| Q3 FY2021Jul 31, 2021 | $557.50M | $205.90M | $763.40M |
| Q2 FY2021Apr 30, 2021 | $522.60M | $196.90M | $719.50M |
| Q1 FY2021Jan 31, 2021 | $507.00M | $173.50M | $680.50M |
| Q4 FY2020Oct 31, 2020 | $506.30M | $175.30M | $681.60M |
| Q3 FY2020Jul 31, 2020 | $449.30M | $128.90M | $578.20M |
| Q2 FY2020Apr 30, 2020 | $402.20M | $122.70M | $524.90M |
| Q1 FY2020Jan 31, 2020 | $485.20M | $161.00M | $646.20M |

